Abstracts tagged "B-Cell Targets"

Abstract Number: 2598 • ACR Convergence 2023
6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells
Christina Bergmann¹, Fabian Müller², Janina Auth³, Jule Taubmann⁴, Michael Aigner⁵, Dagmar Werner⁶, Andreas Wirsching⁷, Johannes Knitza⁸, Hermina Györfi⁹, Jörg Distler¹⁰, Andreas Mackensen⁵ and Georg Schett¹¹, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen, Medicine 3, Erlangen, Germany, ⁴Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷University Hospital Erlangen, Department of Internal Medicine 3, Erlangen, Germany, ⁸Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁰Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: CD19-targeting CAR-T-cells showed remarkable improvements in autoimmune diseases including refractory lupus erythematodes (1,2) and inflammatory myopathy (3). Moreover, first data of a patient with…
Abstract Number: 0005 • ACR Convergence 2023
Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease
Thomas Guy¹, Hang Liu², Vinay Mahajan², Cory Perugino³, Zachary Wallace⁴, Shauna quinn⁵, Allen Poma⁶, Debra Zach⁷, John Stone⁸ and Shiv Pillai⁹, ¹Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ²Ragon Institute, Cambridge, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Zenas Biopharma, New York, NY, ⁶Zenas Biosciences, New York, NY, ⁷Exagen, Vista, CA, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁹Harvard Medical School, Boston, MA
Background/Purpose: Obexelimab is a bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and ligates FcγRIIb with high affinity. Data from a phase 2 clinical trial…
Abstract Number: 0732 • ACR Convergence 2023
Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?
Roba Ghossan¹, Omar AL TABAA², Alice Combier³, Alexia STEELANDT³, Marion THOMAS³, Olivier Fogel³, Corinne MICELI⁴, Anna Molto³ and Jérôme Avouac⁵, ¹COCHIN HOSPITAL, Paris, France, ²APHP / Cochin Hospital, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France
Background/Purpose: Complete peripheral B cell depletion has been considered as a relevant indicator of short-term response to rituximab (RTX) in rheumatoid arthritis (RA). The purpose…
Abstract Number: 1533 • ACR Convergence 2023
Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study
Giacomo De Luca¹, Corrado Campochiaro², Fabio Cacciapaglia³, Nicoletta Del Papa⁴, Elisabetta Zanatta⁵, Paolo Airò⁶, Maria Grazia Lazzaroni⁶, Dilia Giuggioli⁷, Maria De Santis⁸, Gabriella Alonzi⁹, Stefano Stano¹⁰, Marco Binda⁵, Beatrice Moccaldi⁵, Antonio Tonutti¹¹, Florenzo Iannone¹², Maria Antonietta D'Agostino⁹, Lorenzo Dagna¹³, marco Matucci Cerinic¹⁴ and Silvia Bosello¹⁵, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁴Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy, ⁵Rheumatology Unit, Padova University Hospital, Padova, Italy, ⁶Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁷Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁸Reumatologia e Immunologia Clinica, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, ⁹Scleroderma Unit, Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰Rheumatology Unit - DiMePRe-J University of Bari, Bari, Italy, ¹¹Humanitas University and Humanitas Research Hospital, Rozzano, Italy, ¹²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹³Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Rituximab(RTX) has been used for the management of systemic sclerosis(SSc). Its efficacy has been recently confirmed in a phase III clinical trial with extension…
Abstract Number: 0006 • ACR Convergence 2023
Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile
Dianru wang¹, Wenming Ren², lu su¹, yuan lin¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China, ²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pudong New District, China
Background/Purpose: Glucocorticoids (GCs) are the first-line anti-inflammatory treatment for many autoimmune diseases, but long-term systemic administration of GCs is associated with unwanted side effects, which…
Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Jule Taubmann¹, Fabian Müller², Michael Aigner³, Ioanna Minopoulou⁴, Johannes Knitza⁵, Dagmar Werner⁶, Christina Bergmann⁷, Gerhard Kroenke⁸, Andreas Mackensen³ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁸Charite Berlin, Berlin, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
Abstract Number: 1633 • ACR Convergence 2023
Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease
Stephanie Finzel¹, Andrea Grioni², Benjamin A Fisher³, Athena S Papas⁴, Alexandre Avrameas², Danny Tuckwell², Jonas Zierer², Celine Rauld², Valeria De Luca², Enrico Ferrero², Andre Nogueira da Costa², Rainer Hillenbrand², Isabelle Isnardi² and Wolfgang Hueber², ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³University of Birmingham, Birmingham, United Kingdom, ⁴Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA
Background/Purpose: Ianalumab (VAY736) is an afuscosylated monoclonal antibody targeting the B cell activating factor receptor (BAFFR) that depletes B cells via enhanced antibody dependent cellular…
Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Ana Merino-Vico¹, Jan Piet van Hamburg¹, Paul Tuijnenburg¹, Aram Al-Soudi¹, Carlo Bonasia², Boy Helder¹, Abraham Rutgers², Wayel H. Abdulahad², Coen A. Stegeman², Jan-Stephan Sanders², Laura Bergamaschi³, Paul A. Lyons³, Theo Bijma², Laura Van Keep¹, Kirsten wesenhagen¹, Aldo Jongejan¹, Henric Olsson⁴, Niek De Vries¹, Taco W. Kuijpers¹, Peter Heeringa² and Sander Tas⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Cambridge, Cambridge, United Kingdom, ⁴AstraZeneca, Gothenburg, Sweden, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…
Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Brad Rovin¹, Jorge Ross Terres², Sophia Giang³, Thomas Schindler⁴, Armando Turchetta⁵, Jay Garg², Richard Furie⁶, William F. Pendergraft III² and Ana Malvar⁷, ¹Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Genentech, Inc., San Francisco, CA, ⁴F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶Northwell Health, Manhasset, NY, ⁷Hospital Fernandez, Buenos Aires, Argentina
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
Abstract Number: 1813 • ACR Convergence 2023
Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Inés Pérez Sancristóbal¹, Maria Paula Alvarez Hernandez¹, kauzar Mohamed Mohamed², Maria Rodriguez Laguna¹, Cristina Martinez³, Esther Toledano³, Dalifer Freites⁴, Benjamin Fernandez¹, María Rodero³, Cecilia Bravo³, Antonia Rodrígez de la Peña⁵, Silvia Sanchez - Ramon⁵, Gloria mato Chain⁶ and Gloria Candelas¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Department of Immunology, Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clinico San Carlos, Rheumatology Deparment, Madrid, Spain, ⁴Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, ⁶Department of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Data on cellular and humoral immunogenicity triggered by SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases (ARD) are limited. While current vaccine efforts have…
Abstract Number: 0089 • ACR Convergence 2023
Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases
Daniel Patton, Meghan Maurer, Nadine Morgan, Minh Pham, Daniel Boster, Justin Huard, Cathy Tan, Rachael Fasnacht, Monica Childs, Gleda Hermansky, Alex Chen, Susan Julien, Jennifer Gardell, Cathy McMahan, Courtney Crane and Kristine Swiderek, Mozart Therapeutics, Seattle, WA
Background/Purpose: In healthy individuals, CD8 Treg activation leads to selective elimination of aberrantly activated self-reactive CD4 T cells to maintain immune balance. The CD8 Treg…
Abstract Number: 0904 • ACR Convergence 2023
KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease
Soo Park¹, Gloria Lutzny-Geier², Natalia Giltiay¹, Jazmin Bravo¹, Simone Sandoval¹, Joseph Cheng¹, Catherine Dong¹, Nicole Khoshnoodi¹, Ames Register¹, Daniel Anaya¹, Michael Aigner³, Andreas Mackensen³, Georg Schett⁴, Charles Kaplan¹, Dominic Borie¹, James Chung¹ and Tom Van Blarcom⁵, ¹Kyverna Therapeutics, Emeryville, CA, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Kyverna Therapuetics, Emeryville, CA
Background/Purpose: A significant unmet need remains in the treatment of relapsed and/or refractory B cell-driven autoimmune diseases, including systemic lupus erythematosus (SLE),systemic sclerosis (SSc), and…
Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Cristina Calomarde Gomez¹, Raquel Ugena García¹, Julia Valera², Melisa Mena², Maria Esteve², Irma Casas², jose Antonio Dominguez-Benitez², lidia Carabias-Ane², isaac Nuño-Ruiz², Cristina ramo-Tello², Javier Santesmases², Lourdes Mateo Soria³ and Melania Martinez Morillo¹, ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…
Abstract Number: 0204 • ACR Convergence 2023
Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases
Claire Rempenault¹, Cedric Lukas², Léa Tardivon³, Claire Daien⁴, Bernard G. Combe⁵, Philippe GUILPAIN³ and JACQUES MOREL⁶, ¹Universary Hospital of Montpellier, Montpellier, France, ²CHU Montpellier, Montpellier, France, ³University of Montpellier, Montpellier, France, ⁴University Hospital, Montpellier, France, ⁵Department of Rheumatology, Montpellier University, Montpellier, France, ⁶Protocole thérapeutique immuno-rhumatologie, Montpellier, France
Background/Purpose: Literature data on the increased risk of severe infection regarding hypogammaglobinemia related to RTX in IMID are controversial and sparse. We proposed to evaluate…
Abstract Number: 0910 • ACR Convergence 2023
17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Kathryn Sullivan, Yong Wang, Winn Chatham, John Mountz and Hui-chen Hsu, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: While systemic lupus erythematosus (SLE) disproportionally affects women versus men, elevation in estradiol (E2) alone is not sufficient to promote the development of autoantibody…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].